FERRET-SEARCH Archives

Searchable FML archives

FERRET-SEARCH@LISTSERV.FERRETMAILINGLIST.ORG

Options: Use Forum View

Use Monospaced Font
Show Text Part by Default
Show All Mail Headers

Message: [<< First] [< Prev] [Next >] [Last >>]
Topic: [<< First] [< Prev] [Next >] [Last >>]
Author: [<< First] [< Prev] [Next >] [Last >>]

Print Reply
Subject:
From:
Sukie Crandall <[log in to unmask]>
Date:
Fri, 24 Oct 2008 00:39:22 -0400
Content-Type:
text/plain
Parts/Attachments:
text/plain (61 lines)
Ferrets more often are found with dilated cardiomyopathy, but
hypertrophic cardiomyopathy does happen in ferrets and can be very hard
to spot, often needing ultrasound to find it. At times it is not found
until after death.

Here is a new Press Release from
http://www.eurekalert.org/bysubject/biology.php

>Cell Press
>Research uncovers new steps on pathway to enlarged heart
>
>Researchers have new insight into the mechanisms that underlie a
>pathological increase in the size of the heart. The research,
>published by Cell Press in the October 24th issue of the journal
>Molecular Cell, may lead to the development of new strategies for
>managing this extremely common cardiac ailment that often leads to
>heart failure.
>
>High blood pressure, heart valve disease and heart attacks can lead
>to a abnormal thickening of the heart muscle, called myocardial
>hypertrophy. At the molecular level, signals driving myocardial
>hypertrophy, such as elevated levels of catecholamine hormones (i.e.
>adrenaline), activate the Myocyte Enhancer Factor (MEF) proteins. This
>alters gene expression in heart muscle cells and induces an adverse
>developmental paradigm known to cardiologists as the "fetal gene
>response".
>
>"Previous research has shown that the signaling pathways leading to
>MEF2 are altered during pathological cardiac hypertrophy," says senior
>study author Dr. John D. Scott, a Howard Hughes Medical Institute
>Investigator from the Department of Pharmacology at the University of
>Washington. "Although we know that enzymes called histone deacetylases
>(HDACs) control MEF2 activity, it was not clear that HDACs and MEF2
>were integrated into a larger signaling unit."
>
>To further identify the molecular mechanisms associated with cardiac
>hypertrophy, Dr. Scott and colleagues studied cardiac A-Kinase
>Anchoring Proteins (AKAPs), which are known to play a critical role in
>organizing signaling complexes in response to catecholamine hormones
>and transmitted signals within cells.
>
>The researchers found that AKAP-Lbc functions as a scaffolding protein
>that selectively directs catecholamine signals to the transcriptional
>machinery to potentiate the hypertrophic response. "Our study supports
>a model where AKAP-Lbc facilitates activation of protein kinase D,
>which in turn phosphorylates the histone deacetylase HDAC5 to promote
>its export from the nucleus. The reduction in nuclear HDAC5 favored
>MEF2 transcription and the onset of cardiac hypertrophy."
>
>These studies reveal a role for AKAP-Lbc in which increased expression
>of the anchoring protein selectively amplifies a signaling pathway
>that drives cardiac muscle cells to a pathophysiological outcome.
>"It will be important to explore the role of the AKAP-Lbc/PKD/HDAC5
>signaling pathway in whole animal models to establish whether AKAP-Lbc
>is a valid biomarker for hypertrophic cardiomyopathy and to determine
>which genes are initiated upon up-regulation of the anchoring
>protein," offers Dr. Scott.

[Posted in FML 6133]


ATOM RSS1 RSS2